Literature DB >> 12210656

Olanzapine in the treatment of anorexia nervosa: an open label trial.

Pauline S Powers1, Carlos A Santana, Yvonne S Bannon.   

Abstract

OBJECTIVE: The primary goal of the study was to determine if olanzapine is effective in producing weight gain in patients with anorexia nervosa.
METHOD: Twenty patients with anorexia nervosa (restricting or binge/purge subtype) without schizophrenia, schizoaffective disorder, or bipolar disorder enrolled in an open label study of olanzapine 10 mg. Patients attended weekly drug monitoring sessions and weekly group medication adherence sessions that provided psychoeducation.
RESULTS: Eighteen patients received the drug and 14 patients completed the 10-week study. The four drop-outs had gained a mean of 3.25 lb at their last visit. Of the 14 patients who completed the study, 10 gained an average of 8.75 lb and 3 of these patients attained their ideal body weight. The remaining four patients who completed the study lost a mean of 2.25 lb. DISCUSSION: These findings are promising with clinically significant weight gain in an outpatient setting during a brief 10-week period. Copyright 2002 by Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210656     DOI: 10.1002/eat.10084

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  16 in total

1.  Management of anorexia nervosa revisited.

Authors:  Janice Russell
Journal:  BMJ       Date:  2004-02-28

Review 2.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

3.  Olanzapine use in adolescent anorexia nervosa.

Authors:  K Dennis; D Le Grange; J Bremer
Journal:  Eat Weight Disord       Date:  2006-06       Impact factor: 4.652

4.  Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.

Authors:  Vikas Duvvuri; Taya Cromley; Megan Klabunde; Kerri Boutelle; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-02-22       Impact factor: 4.861

5.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

Review 6.  The psychopharmacotherapy of anorexia nervosa: clinical, neuroendocrine and metabolic aspects.

Authors:  G Abbate Daga; L Gianotti; V Mondelli; R Quartesan; S Fassino
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

7.  A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study.

Authors:  Jennifer Hagman; Jane Gralla; Eric Sigel; Swan Ellert; Mindy Dodge; Rick Gardner; Teri O'Lonergan; Guido Frank; Marianne Z Wamboldt
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-08-05       Impact factor: 8.829

8.  Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.

Authors:  M Aragona
Journal:  Eat Weight Disord       Date:  2007-09       Impact factor: 4.652

9.  Eighty-five per cent of what? Discrepancies in the weight cut-off for anorexia nervosa substantially affect the prevalence of underweight.

Authors:  J J Thomas; C A Roberto; K D Brownell
Journal:  Psychol Med       Date:  2008-09-08       Impact factor: 7.723

10.  A review of medication use for children and adolescents with eating disorders.

Authors:  Jennifer Couturier; James Lock
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.